IP Library Granted Patent US 10,106,505
Granted Patent B2
US 10,106,505 · App. 15/895,244 · Granted Oct 23, 2018

Composition and methods for modulating a kinase cascade

Inventor: David G. Hangauer, Jr. (Lancaster, NY)
Assignee: Athenex, Inc.
C07D213/56C07C303/32C07C309/29
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,505
App. No.
15/895,244
Granted
Oct 23, 2018
Kind
B2
Abstract

The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.

Claims (26)

1. A process of preparing compound 1:

or a pharmaceutically acceptable salt or solvate thereof, comprising Step 3:

converting compound 12 to compound 1:

2. The process of claim 1 , further comprising Step 2:

converting compound 11 to compound 12:

3. The process of claim 2 , wherein Step 2 comprises reacting compound 11 with trimethylsilylchloride in a polar protic solvent.

4. The process of claim 3 , wherein the polar protic solvent is selected from methanol, ethanol, and isopropanol.

5. The process of claim 2 , wherein the reaction is carried out at a temperature from about 40° C. to about 60° C.

6. The process of claim 2 , further comprising Step 1:

converting compound 10 to compound 11:

7. The process of claim 6 , wherein in Step 1 compound 10 is reacted with a base and acetonitrile in a polar aprotic solvent to form compound 11.

8. The process of claim 7 , wherein the polar aprotic solvent is selected from tetrahydrofuran, ethyl acetate, acetone, and dimethylsulfoxide.

9. The process of claim 7 , wherein the base is potassium bis(trimethylsilyl)amide.

10. The process of claim 6 , wherein the reaction is carried out at a temperature less than about 10° C.

11. The process of claim 1 , wherein in Step 3 compound 12 is reacted with reagent A in an ether solvent to form compound 1.

12. The process of claim 11 , wherein the ether solvent is selected from anisole and diethyl ether.

13. The process of claim 1 , wherein the reaction is carried at a temperature from about 120° C. to about 160° C.

14. The process of claim 1 , further comprising reacting compound 1 with benzenesulfonic acid in the presence of a polar aprotic solvent and an ether solvent.

15. A process of preparing the benzenesulfonate salt of compound 1:

comprising

converting compound 12 to compound 1:

wherein compound 12 is formed by reacting compound 11:

with trimethylsilylchloride in a polar protic solvent, and

reacting compound 1 with benzenesulfonic acid in the presence of a polar aprotic solvent and an ether solvent.

16. The process of claim 15 , wherein the polar aprotic solvent is selected from acetonitrile, ethyl acetate, and tetrahydrofuran.

17. The process of claim 15 , wherein the ether solvent is selected from anisole and diethyl ether, preferably wherein the ether solvent is anisole.

Assignments (6)
SECURITY INTEREST Recorded Jun 22, 2020
From: ATHENEX, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 053005/0657 →
RELEASE OF SECURITY INTEREST Recorded Jun 19, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ATHENEX, INC.
Reel/Frame 052990/0677 →
PATENT SECURITY AGREEMENT Recorded Jul 3, 2018
From: ATHENEX, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047247/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2018
From: HANGAUER, DAVID G., JR.
To: KINEX PHARMACEUTICALS, LLC
Reel/Frame 044914/0900 →
CHANGE OF NAME Recorded Feb 13, 2018
From: KINEX PHARMACEUTICALS, INC.
To: ATHENEX, INC.
Reel/Frame 045316/0646 →
CHANGE OF NAME Recorded Feb 13, 2018
From: KINEX PHARMACEUTICALS, LLC
To: KINEX PHARMACEUTICALS, INC.
Reel/Frame 045317/0811 →
Continuity (4)
Division 14015030 · Aug 30, 2013
Provisional Application 61779868 · Mar 13, 2013
Provisional Application 61695100 · Aug 30, 2012
Related Publication 20180170875A1 · Jun 21, 2018